Literature DB >> 17803346

Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs.

Christoph Schindler1, Peter Bramlage, Martin Thoenes, Carsten Bramlage, Wilhelm Kirch.   

Abstract

OBJECTIVE: Obese patients often present with multiple co-morbid conditions, including hypertension, which are associated with an increased cardiovascular (CV) risk. We aimed to assess the risk factor profiles of primary-care patients with obesity and hypertension in order to estimate their fatal CV risk in total and according to use of various antihypertensive drugs.
METHODS: This was a post-hoc analysis of data from a recent observational study involving 72 479 hypertensive patients in 6989 general practices across Germany. Almost all patients (92.3%) were overweight or obese. The 10-year risk for fatal CV events was determined using the SCORE algorithm as published by the European Society of Cardiology.
RESULTS: Overall, 68% of patients had one or more diseases or conditions in addition to obesity and hypertension. The 10-year fatal CV risk was lowest in the youngest normal weight group (1.7%), and highest in the oldest obese group (26%). Men had a higher risk than women, and risk rose with increasing age. The risk factor profile appeared to differ between patients treated with various antihypertensive classes, e.g. angiotensin II type 1 receptor antagonists were associated with lower risk, diuretics with higher risk. There were moderate differences within drug classes.
CONCLUSIONS: According to this cross-sectional data, fatal CV risk is strongly increased in obese patients, especially in men and in older age groups. While there were strong associations between use of certain drugs and metabolic risk markers and overall fatal CV risk, the causality of these associations remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803346     DOI: 10.2165/00044011-200727100-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  28 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association.

Authors: 
Journal:  BMJ       Date:  2000-03-11

2.  Perceptions of cardiovascular risk among patients with hypertension or diabetes.

Authors:  Bernard D Frijling; Claudia M Lobo; Inge M Keus; Kathleen M Jenks; Reinier P Akkermans; Marlies E J L Hulscher; Ad Prins; Johannes C van der Wouden; Richard P T M Grol
Journal:  Patient Educ Couns       Date:  2004-01

3.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

Authors:  Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  [Antihypertensive drug utilization in obese patients].

Authors:  Peter Bramlage; Carsten Bramlage; Wilhelm Kirch
Journal:  Med Klin (Munich)       Date:  2005-12-15

6.  Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled.

Authors:  Peter Bramlage; David Pittrow; Hans-Ulrich Wittchen; Wilhelm Kirch; Steffen Boehler; Hendrik Lehnert; Michael Hoefler; Thomas Unger; Arya M Sharma
Journal:  Am J Hypertens       Date:  2004-10       Impact factor: 2.689

7.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

8.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

9.  Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

Authors:  Peter W F Wilson; Ralph B D'Agostino; Lisa Sullivan; Helen Parise; William B Kannel
Journal:  Arch Intern Med       Date:  2002-09-09

10.  Waist circumference and not body mass index explains obesity-related health risk.

Authors:  Ian Janssen; Peter T Katzmarzyk; Robert Ross
Journal:  Am J Clin Nutr       Date:  2004-03       Impact factor: 7.045

View more
  1 in total

Review 1.  Local adipose tissue renin-angiotensin system.

Authors:  Lisa A Cassis; Sara B Police; Frederique Yiannikouris; Sean E Thatcher
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.